美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Corgi Beauty, Skincare & Aesthetics ETF

27.97

+0.07240.26%

盤後：27.90-0.0673-0.24%16:10 EDT

成交量：226

成交額：6,313

市值：139.84萬

市盈率：- -

高：27.97

開：27.90

低：27.90

收：27.89

52周最高：29.89

52周最低：24.32

股本：5.00萬

流通股本：5.00萬

量比：2.06

換手率：0.45%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

Hims & Hers回應FTC訴訟：指控忽視公司近三年調查期間提供的充分證據

Hims & Hers Health 回應FTC訴訟：我們立場堅定，將積極捍衞自身權益，堅決駁斥這些毫無根據的指控

Hims & Hers股價暴跌12.2%：路透社稱美國FTC起訴其向Meta和Snap共享用户健康信息

獨家：美國聯邦貿易委員會起訴Hims & Hers，指控其賬單、取消訂閲及隱私操作違規

獨家報導-美國聯邦貿易委員會（FTC）起訴Hims & Hers公司，指控其向Meta和Snap泄露用户健康信息

傑富瑞上調雅詩蘭黛目標價至88美元

艾伯維(ABBV)股票7月28日盤中上漲3.35%：關鍵驅動因素揭曉

TradingKey中文

解讀世界500強排行榜醫藥板塊：強生繼續「霸榜」，禮來排名上升112位，3家中國企業入選

每日经济新闻

Meta和貝萊德將在德克薩斯州EL Paso開發數據中心園區由後者持股80%

环球市场播报

Sarepta任命前艾伯維高管塞韋裏諾為首席執行官後股價上漲

Kenvue 宣佈：FDA 授予泰諾新非處方配方三年市場獨佔權

FDA批准泰諾®與萘普生複方製劑：首款非處方對乙酰氨基酚（650毫克）與萘普生鈉（220毫克）固定劑量組合

美國FDA批准非處方泰諾複方止痛片

美國FDA批准首款對乙酰氨基酚/萘普生非處方組合產品——泰諾聯用萘普生，提供12小時鎮痛效果

艾利科技推出全新創新成果，藉助整合型Align™數字平台提升Invisalign®治療方案規劃與患者參與度

Genmab與艾伯維就Epcoritamab（Duobody®-CD3xCD20）治療復發/難治性瀰漫大B細胞淋巴瘤的3期EPCORE® DLBCL-1試驗作出澄清

Genmab澄清：總生存期（OS）作為美國3期Epcore® DLBCL-1試驗的唯一主要終點，但未能達到

FDA顧問委員會投票支持將Bpc-157肽納入允許藥房配製清單，Hims & Hers Health股價飆升10%

FDA顧問小組投票決定將廣受歡迎的肽BPC-157列入複方製劑清單

美國FDA顧問小組評估肽類限制，業界促放寬

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/GLAM/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"GLAM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLAM\",,,,,undefined,":{"symbol":"GLAM","market":"US","secType":"STK","nameCN":"Corgi Beauty, Skincare & Aesthetics ETF","latestPrice":27.9673,"timestamp":1789675200000,"preClose":27.8949,"halted":0,"volume":226,"hourTrading":{"tag":"盘后","latestPrice":27.9,"preClose":27.9673,"latestTime":"16:10 EDT","volume":6,"amount":167.8038,"timestamp":1789675804115,"change":-0.0673,"changeRate":-0.002406,"amplitude":0},"delay":0,"changeRate":0.0025954565171411904,"floatShares":50000,"shares":50000,"eps":0,"marketStatus":"未開盤","change":0.0724,"latestTime":"09-17 16:00:00 EDT","open":27.9,"high":27.9673,"low":27.9,"amount":6313,"amplitude":0.002413,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789718400000},"marketStatusCode":0,"adr":0,"exchange":"CBOE","adjPreClose":27.8949,"nav":27.86,"aum":1393000,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.9,"preClose":27.9673,"latestTime":"16:10 EDT","volume":6,"amount":167.8038,"timestamp":1789675804115,"change":-0.0673,"changeRate":-0.002406,"amplitude":0},"volumeRatio":2.058291,"impliedVol":0.4432,"impliedVolPercentile":0.6071},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLAM\",,,,,undefined,":{"symbol":"GLAM","floatShares":50000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.058291,"shares":50000,"dividePrice":0,"high":27.9673,"amplitude":0.002413,"preClose":27.8949,"low":27.9,"week52Low":24.3178,"pbRate":"--","week52High":29.89,"institutionHeld":0,"latestPrice":27.9673,"eps":0,"divideRate":0,"volume":226,"delay":0,"ttmEps":0,"open":27.9,"prevYearClose":25.82,"prevWeekClose":28.0254,"prevMonthClose":28.9677,"prevQuarterClose":27.6454,"fiveDayClose":27.7464,"twentyDayClose":28.837,"sixtyDayClose":26.16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GLAM\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GLAM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GLAM\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GLAM\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1132827512","title":"Hims & Hers回應FTC訴訟：指控忽視公司近三年調查期間提供的充分證據","url":"https://stock-news.laohu8.com/highlight/detail?id=1132827512","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132827512?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 01:22","pubTimestamp":1785345728,"startTime":"0","endTime":"0","summary":"针对美国联邦贸易委员会（FTC）的诉讼，Hims & Hers Health Inc. 公司发表声明。公司认为，这起诉讼完全无视了其在近三年调查过程中向FTC提交的大量实质性证据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HMYY","HIMY","HIMZ","BK4196","HEAL","THNR","HIYY","GLAM","HIMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101602756","title":"Hims & Hers Health 回應FTC訴訟：我們立場堅定，將積極捍衞自身權益，堅決駁斥這些毫無根據的指控","url":"https://stock-news.laohu8.com/highlight/detail?id=1101602756","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101602756?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 01:21","pubTimestamp":1785345694,"startTime":"0","endTime":"0","summary":"面对美国联邦贸易委员会（FTC）提起的诉讼，Hims & Hers Health Inc.（HIMS）正式发声。该公司明确表态，坚信自身立场完全站得住脚，并誓言将采取强有力的法律行动，以抵御这些被其定性为“毫无根据”的指控。在官方回应中，Hims & Hers Health强调，他们不会屈服于压力，反而会以更加积极且坚决的姿态，为自己进行辩护。这一声明，既是对当前法律挑战的直接回应，也彰显了其捍卫公司声誉与商业模式的决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMZ","GLAM","HIYY","HIMS","HIMY","THNR","HMYY","BK4196","HEAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143480394","title":"Hims & Hers股價暴跌12.2%：路透社稱美國FTC起訴其向Meta和Snap共享用户健康信息","url":"https://stock-news.laohu8.com/highlight/detail?id=1143480394","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143480394?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 00:46","pubTimestamp":1785343563,"startTime":"0","endTime":"0","summary":"Hims & Hers Health Inc.股价今日大幅下挫，跌幅高达12.2%。据路透社报道，美国联邦贸易委员会 已对该公司提起诉讼，指控其未经用户同意，擅自将用户的健康数据传送给Meta Platforms, Inc.和Snap Inc.。如果这些指控属实，Hims & Hers将面临严重的法律后果和声誉危机。事件的核心在于，Hims & Hers被指控利用了其平台上用户的健康信息，并将这些数据分享给Meta和Snap这两大社交媒体巨头。目前，Hims & Hers方面尚未就此事件发表正式声明，但市场显然已经用脚投票，给出了最直接的回应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1992135399.USD","LU2505996509.AUD","IE0034235303.USD","LU0256863811.USD","LU0943347566.SGD","LU1564329032.USD","LU2065171402.SGD","LU2168564065.EUR","IE000F7OJYX1.SGD","IE000KEQY171.SGD","LU1548497426.USD","IE0009356076.USD","LU1674673691.USD","LU1791710400.SGD","LU2272731865.HKD","LU2592432038.USD","LU0203201768.USD","IE00BJLML261.HKD","SG9999015945.SGD","LU0149725797.USD","LU0882574139.USD","LU2106854487.HKD","LU1674673428.USD","METW","METU","BK4507","LU1861558580.USD","LU2065170008.USD","LU1116320737.USD","LU0109391861.USD","LU2505996681.GBP","LU0444971666.USD","LU2552382058.USD","LU2357305700.SGD","LU1815333072.USD","LU0109392836.USD","LU1720051017.SGD","LU0640476718.USD","LU0320765489.SGD","LU0053666078.USD","LU2404859667.USD","LU0157215616.USD","IE00B5949003.HKD","LU0690374961.EUR","LU1868836591.USD","LU0211328371.USD","LU0795875086.SGD","LU1815336760.USD","LU0949170426.SGD","LU0130102774.USD","LU2462591350.SGD","LU0133085943.USD","LU2746668974.SGD","LU2456880835.USD","LU0256863902.USD","LU0354030511.USD","LU1116320901.HKD","LU2404859741.USD","LU2487616109.SGD","HIMS","BK4524","HIMZ","LU1732799900.SGD","LU2250418816.HKD","LU0912757837.SGD","LU0683600562.USD","IE00B7KXQ091.USD","LU0211327993.USD","LU0348723411.USD","LU1242518931.SGD","BK4551","LU2265009873.SGD","LU2430703251.USD","LU2125154935.USD","BK4588","LU2764263203.CNY","LU2860962120.EUR","LU0072461881.USD","IE00B19Z8W00.USD","LU0077335932.USD","SG9999002224.SGD","LU0265550359.USD","LU1868836757.USD","SG9999015978.USD","IE00BQXX3D17.EUR","LU0215105999.USD","HEAL","LU1301847155.USD","LU2756315318.SGD","LU1064131342.USD","LU1489326972.SGD","IE00B3SWFQ91.USD","LU1861559042.SGD","LU1496350502.SGD","LU0820562030.AUD","LU1868837300.USD","LU0070302665.USD","LU0354030438.USD","LU2264538146.SGD","LU2360106780.USD","LU1564329461.SGD","IE00BQXX3F31.USD","LU1074936037.SGD","IE00B7SZLL34.SGD","IE00BMPRXN33.USD","LU1267930490.SGD","LU1791710582.SGD","LU1084165304.USD","LU0225283273.USD","LU2317271919.USD","LU2168564149.EUR","RSPC","SGXZ31699556.SGD","SG9999004303.SGD","LU1814569148.SGD","LU1974910355.USD","LU1629891620.HKD","LU1435385759.SGD","BK4587","BK4196","LU0949170772.SGD","IE00BJTD4V19.USD","LU1988902786.USD","LU0162691827.USD","LU0079474960.USD","LU0661504455.SGD","LU0070217475.USD","LU1823568750.SGD","LU0553294199.USD","HIMY","SG9999017495.SGD","LU0061474960.USD","LU1718418525.SGD","BK4576","IE000BZT7R73.USD","IE00BWXC8680.SGD","VOX","LU0265550946.USD","LU1201861249.SGD","LU2237957902.USD","IE0000B7K699.USD","LU2417539215.USD","IE00BKDWB100.SGD","LU0545039389.USD","LU0208291251.USD","LU1235294995.USD","BK4508","LU1699723380.USD","LU0979878070.USD","IE00B19Z3581.USD","LU1119994496.HKD","LU2065169927.USD","LU1551013342.USD","LU2552382132.HKD","LU1868836914.USD","LU0823434583.USD","SOCL","LU1642822529.SGD","LU2361044949.HKD","LU0310799852.SGD","SG9999015986.USD","LU2361045086.USD","LU2133065610.SGD","IE00B1BXHZ80.USD","FBL","SG9999014898.SGD","LU0642271901.SGD","LU1066053197.SGD","LU0082616367.USD","META","BK4543","LU0648001328.SGD","IE00B1XK9C88.USD","LU0203202063.USD","SGXZ23171101.USD","BK4592","LU2360032135.SGD","IE000MB6IJN5.SGD","LU0417517546.SGD","LU2746668461.USD","SGXZ51526630.SGD","LU2272731782.SGD","LU0345769128.USD","HIYY","LU0056508442.USD","LU2462157665.USD","LU0353189763.USD","LU2720916845.USD","LU0985489474.SGD","SG9999001077.SGD","LU2272731600.USD","LU2420271590.USD","XLC","LU0787776722.HKD","LU2236285917.USD","SGXZ81514606.USD","LU0080751232.USD","LU2054465674.USD","LU1670627923.USD","IE00BK4W5M84.HKD","IE0001KFT4U8.USD","LU0211331839.USD","FBY","IE00BK4W5L77.USD","LU2322448791.USD","HK0000304805.HKD","LU2168564222.USD","LU1261432733.SGD","IE00B19Z8X17.USD","LU0174119429.USD","IE00BFSS7M15.SGD","IE00BN29S564.USD","SG9999015952.SGD","LU0308772762.SGD","LU0708995401.HKD","LU0878866978.SGD","LU0820561909.HKD","LU0006306889.USD","LU2097829019.USD","LU0154236417.USD","LU2247934214.USD","LU0786609619.USD","LU1670710588.SGD","HK0000304797.USD","LU0738911758.USD","LU2242650005.HKD","LU1868837136.USD","THNR","IE00B19Z3B42.SGD","LU0203347892.USD","LU2213496289.HKD","IE0003U64NQ7.SGD","IE0034235188.USD","LU2065171311.SGD","IE00BMPRXR70.SGD","BK4554","LU0724617625.USD","LU2430703095.HKD","IE00B4YYXB79.USD","IE00BJTD4N35.SGD","LU1366333091.USD","SG9999014880.SGD","IE000ITXATA3.USD","LU1670628061.USD","SG9999014914.USD","IE0004445239.USD","LU1670710661.SGD","LU0957808578.USD","LU1571399168.USD","LU0267386448.USD","LU1127390331.HKD","TRUC","LU1992135472.HKD","LU0444973449.USD","LU2756315664.SGD","LU0784385170.HKD","LU1153585028.USD","HK0000914660.USD","LU0823421333.USD","LU1551013425.SGD","LU2087625088.SGD","GLAM","LU1242518857.USD","LU0106261372.USD","LU2458330169.SGD","IE0005OL40V9.USD","LU0889565833.HKD","LU0203345920.USD","LU0784385840.USD","LU0068578508.USD","LU2381873111.SGD","LU0097036916.USD","LU2087621335.USD","XDAT","NULC","LTL","LU1232071149.USD","LU0820561818.USD","LU1035775433.USD","LU1720051108.HKD","LU0210533765.USD","LU0072462426.USD","LU0719512351.SGD","LU0198837287.USD","LU0316494557.USD","LU2764262908.HKD","LU2023250843.SGD","LU1267930730.SGD","LU2461242641.AUD","HMYY","LU1803068979.SGD","IE00BMPRXQ63.HKD","LU1066051498.USD","LU0689472784.USD","IE000YTNTUN2.SGD","LU1839511570.USD","LU2403377893.USD","SG9999018865.SGD","LU0061474705.USD","HK0000914686.HKD","BK4077","LU2063271972.USD","LU0672654240.SGD","LU0466842654.USD","LU1852331112.SGD","SG9999002232.USD","LU0795875169.SGD","LU1280957306.USD","LU2430703178.SGD","LU1914381329.SGD","LU0314104364.USD","LU0061475181.USD","IE000WAW04H5.SGD","LU2552382215.SGD","SGXZ99366536.SGD","LU0210528500.USD","LU1697837992.HKD","LU0784383803.USD","IE0004445015.USD","METD","OGIG","SG9999014906.USD","LU2347655073.USD","LU0476273544.USD","LU0353189680.USD","LU0980610538.SGD","LU2023250504.SGD","LU2168564495.EUR","LU0784384876.USD","BK4585","LU2602419157.SGD","METV","GB00B4LPDJ14.GBP","LU0345769631.USD","LU0823434740.USD","LU2463028550.USD","LU0234570918.USD","LU0320765059.SGD","LU0964807845.USD","LU1316542783.SGD","LU0127658192.USD","LU1145028129.USD","IE00BJJMRY28.SGD","GB00B4QBRK32.GBP","LU2473716301.USD","LU1732800096.USD","LU1429558221.USD","LU0985320562.USD","LU0096362180.USD","GB00BDT5M118.USD","LU2361044865.SGD","IE000SO60NU8.SGD","IE0002270589.USD","LU1059921491.USD","LU0323591593.USD","LU1003077747.HKD","LU2322448957.HKD","LU0433182093.SGD","LU0726765562.USD","IE00B4JS1V06.HKD","LU0011850046.USD","LU1804176565.USD","IE00B19Z9505.USD","GAMR","GXPC","LU0823421416.USD","IE000W1ABFV2.USD","LU1670711040.USD","LU2458330243.SGD","LU1778281490.HKD","LU1069344957.HKD","LU1564329628.SGD","IE00BQXX3C00.GBP","IE00BFSS8Q28.SGD","IE00BJJMRX11.SGD","LU0552385451.USD","LU0690374615.EUR","LU0096364046.USD","LU2168563687.JPY","LU1917777945.USD","LU2237957811.SGD","LU2326559502.SGD","FBYY","LU2125154778.USD","LU1046421795.USD","SNAP","LU1564329115.USD","SG9999018857.SGD","LU0170899867.USD","LU0788109477.HKD","LU2023250330.USD","LU2347655156.SGD","LU0276348264.USD","LU0957791311.USD","LU0234572021.USD","SNAG","LU0528227936.USD","LU0210536198.USD","LU2543165471.USD","LU1670711123.USD","IE0009G5SDU7.USD","FCOM","LU2764263039.SGD","LU2896262040.SGD","IE00B775H168.HKD","LU1366192091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184720821","title":"獨家：美國聯邦貿易委員會起訴Hims & Hers，指控其賬單、取消訂閲及隱私操作違規","url":"https://stock-news.laohu8.com/highlight/detail?id=1184720821","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184720821?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 00:31","pubTimestamp":1785342705,"startTime":"0","endTime":"0","summary":"独家消息源透露，美国联邦贸易委员会（FTC）已正式对远程医疗公司Hims & Hers Health Inc.提起法律诉讼，矛头直指其收费流程、订阅取消政策以及用户隐私保护方面的多项不规范操作。一位FTC发言人在官方声明中确认了这一消息，使得这起备受瞩目的监管行动公之于众。据悉，此次诉讼的核心争议点在于，该公司是否在账单结算、取消订阅的便捷性上误导消费者，并可能涉及不当收集或使用用户健康数据。这一法律行动的细节仍在持续发酵中，市场对此反应强烈，投资者正密切关注后续的庭审进展和潜在处罚结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEAL","HIMY","HIMZ","THNR","GLAM","HIYY","HMYY","HIMS","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655892781","title":"獨家報導-美國聯邦貿易委員會（FTC）起訴Hims & Hers公司，指控其向Meta和Snap泄露用户健康信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2655892781","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655892781?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 00:30","pubTimestamp":1785342638,"startTime":"0","endTime":"0","summary":"独家报导-美国联邦贸易委员会起诉Hims & Hers公司，指控其向Meta和Snap泄露用户健康信息Jody Godoy路透7月29日-美国联邦贸易委员会的一位发言人表示，该委员会正在起诉Hims & Hers，指控这家远程医疗平台尽管承诺保护隐私，却仍将用户的健康数据分享给在线广告商，并存在欺骗性的计费和取消服务行为。FTC还计划指控称，Hims & Hers还故意设置障碍，使用户难以取消订阅。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL4T43V1U1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMY","HIMS","HMYY","HEAL","HIMZ","THNR","BK4196","GLAM","HIYY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655863822","title":"傑富瑞上調雅詩蘭黛目標價至88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655863822","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655863822?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 17:16","pubTimestamp":1785316594,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2404859667.USD","LU1064131342.USD","LU2552382132.HKD","LU2404859741.USD","LU2552382215.SGD","UDN","LU2552382058.USD","BK4504","BK4533","BK4585","LU0690374615.EUR","LU1988902786.USD","BK4183","UUP","LU2264538146.SGD","BK4558","EL","GLAM","BK4548","BK4588","LU0690374961.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655889943","title":"艾伯維(ABBV)股票7月28日盤中上漲3.35%：關鍵驅動因素揭曉","url":"https://stock-news.laohu8.com/highlight/detail?id=2655889943","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655889943?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 23:16","pubTimestamp":1785251791,"startTime":"0","endTime":"0","summary":"• Skyrizi和Rinvoq的增长抵消了修美乐（Humira）生物类似药竞争带来的收入损失。\n• 在公布强劲的季度业绩后，艾伯维上调了全年调整后盈利指引。\n• 神经科学和肿瘤学领域积极的后期临床试验数据推动了中期增长。","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262059169-market-movers-abbv-20260728","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930490.SGD","LU0203347892.USD","LU1162221912.USD","PPH","IE00B3PB1722.GBP","LU0170899867.USD","LU2347655156.SGD","FHLC","LU1670628061.USD","IXJ","LU1989771016.USD","LU2129689605.HKD","LU0472753341.HKD","ABBV","LU0882574055.USD","LU2433249047.HKD","PJP","AGNG","LU0942090050.USD","IE0009355771.USD","TRUH","LU2087621335.USD","IE000BZT7R73.USD","IE00BDGV0183.EUR","JDOC","LU1061106388.HKD","IE00B42XCP33.USD","LU0198837287.USD","IE00BJT1NW94.SGD","LU0861579265.USD","RXL","GLAM","IYH","IE00BGHQF631.EUR","LU0124676726.USD","LU2133065610.SGD","LU2089984988.USD","LU2357627491.SGD","IE0002141913.USD","MEDX","FTXH","SG9999003800.SGD","BK4585","LU1057294990.SGD","LU0868494617.USD","LU0943347566.SGD","IE00BJJMRZ35.SGD","LU1267930573.SGD","VHT","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654007935","title":"解讀世界500強排行榜醫藥板塊：強生繼續「霸榜」，禮來排名上升112位，3家中國企業入選","url":"https://stock-news.laohu8.com/highlight/detail?id=2654007935","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654007935?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 20:51","pubTimestamp":1785243108,"startTime":"0","endTime":"0","summary":"7月28日，2026年《财富》世界500强榜单正式发布。《每日经济新闻》记者注意到，医疗健康板块作为全球五大支柱行业之一，共有31家企业上榜。其中，礼来公司排名从2025年的336位上升至今年的224位，成为今年上涨最快的10家公司之一。中国公司中，中国医药集团、上海医药、广药集团3家公司再次入围。《每日经济新闻》记者注意到，位居医疗健康相关企业榜首的是联合健康集团。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607283823749452.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607283823749452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4559","LU2491050154.USD","LU1989772840.SGD","LU0557290698.USD","LU1280957306.USD","IE00BJLML261.HKD","JNJ","LU2896262040.SGD","SG9999015952.SGD","LU0052756011.USD","SGXZ51526630.SGD","LU2023250843.SGD","IE00BLSP4239.USD","LU0889566641.SGD","LU2552382132.HKD","LU1839511570.USD","LU0122379950.USD","MEDX","LU0672654240.SGD","BK4516","LU2462157665.USD","LU2750360641.GBP","LU1929549753.HKD","LU2361044949.HKD","LU0130102774.USD","LU2213496289.HKD","BK4599","IE00BGHQF631.EUR","IE00B4JS1V06.HKD","LU0109391861.USD","LU0094547139.USD","LU1066053197.SGD","LU0289739699.SGD","LU2999663052.SGD","LU2237438978.USD","LU0738911758.USD","IE00B775H168.HKD","LU2133065610.SGD","LU2106854487.HKD","LU1883839398.USD","IE00B19Z3B42.SGD","LU2456880835.USD","LU2592432038.USD","LU0985320562.USD","LU1023059063.AUD","LU2237443895.HKD","LU0353189763.USD","LU1003077747.HKD","LU1506573853.SGD","LU2089284900.SGD","LU2089283258.USD","LU2430703178.SGD","LU0234572021.USD","LU2237443622.USD","LU0708995401.HKD","LU2168563687.JPY","BK4007","LU0861579265.USD","LU0225284248.USD","AMGN","LU2462591277.SGD","LU1934455863.HKD","LU2357305700.SGD","LU0210528500.USD","LU1791710582.SGD","LU1084165304.USD","LU2403377893.USD","NVS","LU0128525689.USD","LU2362541273.HKD","HRTS","SGXZ31699556.SGD","IHF","IE00B1BXHZ80.USD","LU0689472784.USD","LU1974910355.USD","LU2108987350.USD","LU0323591593.USD","LU2279689827.SGD","LU2357627491.SGD","LU0708994859.HKD","IE00B19Z9P08.USD","LU1145028129.USD","LU0661504455.SGD","LU0211327993.USD","IE0001KFT4U8.USD","LU2265009873.SGD","LU2552382215.SGD","IE000WAW04H5.SGD","LU2471134796.USD","LU1983299246.USD","LU1037948897.HKD","IXJ","LU2111349929.HKD","IE00BKPKM429.USD","IE00BKDWB100.SGD","LU1032466523.USD","LU0225771236.USD","LU0149725797.USD","LU0072461881.USD","TRUH","LU1032955483.USD","LU0787776722.HKD","LU1069347547.HKD","IE0009355771.USD","LU0882574139.USD","IE00BWXC8680.SGD","LU2324357040.USD","LU2746668974.SGD","LU0472753341.HKD","SG9999014575.USD","LU1778281490.HKD","LU2168564065.EUR","LU2242649171.HKD","LU1585245621.USD","LU2750360997.AUD","UNH","LU1934455194.USD","LU0053666078.USD","IE00BFSS7M15.SGD","LU2237443978.SGD","LU0310799852.SGD","LU0187121727.USD","LU0553294199.USD","MEDI","LU1989771016.USD","LU0426412945.USD","ABBV","LU0417517546.SGD","IE00BSNM7G36.USD","LU1244550577.SGD","LU0545039389.USD","IE00BJT1NW94.SGD","LU1066051498.USD","IE0034235303.USD","LU2168564149.EUR","LU0320765489.SGD","LU2746668461.USD","FHLC","LU0211328371.USD","LU1804176565.USD","LU2023250504.SGD","LU1854104046.USD","LU0466842654.USD","LU0965509010.AUD","IE00BK4W5M84.HKD","LU1153585028.USD","SG9999015986.USD","LU0203201768.USD","IBBQ","GLAM","LU0795875169.SGD","BK4533","LU2505996681.GBP","LU0289961442.SGD","LU2112291526.USD","SG9999018857.SGD","LU0109394709.USD","LU0114720955.EUR","LU2491049909.HKD","LU0208291251.USD","LU0385154629.USD","LU0198837287.USD","IBB","LU0859254822.USD","LU0238689110.USD","LU2264538146.SGD","LU1043141396.HKD","LU0689626769.HKD","IE0004445239.USD","LU2471134952.CNY","IE00BZ9MQY76.HKD","LU0965509283.SGD","LU0432979614.USD","LU0726765562.USD","LU0823434583.USD","SG9999017495.SGD","LU0820562030.AUD","LU0234570918.USD","MRK","LU0820561818.USD","LU0143551892.USD","IE00BFXG1179.USD","IE0002141913.USD","LU0070217475.USD","LU0265550946.USD","LU0048584097.USD","LU2087625088.SGD","LU2244417387.USD","BK4504","LU1069344957.HKD","LU1291159041.SGD","LU1267930813.SGD","LU0965508806.USD","BK4139","LU1323610961.USD","LU1732799900.SGD","LU1267930227.SGD","BIB","SG9999013999.USD","LU0321505868.SGD","LU0128525929.USD","LU1267930730.SGD","BMED","LU1629891620.HKD","ILDR","LU1064131342.USD","LU1074936037.SGD","LU2242652126.USD","BK4585","LU2168564495.EUR","LU0265550359.USD","LU0320765646.SGD","LU1894683348.USD","LU2063271972.USD","LU0868494617.USD","IE00B19Z9Z06.USD","LU1917777945.USD","LU0306806265.USD","LU1119994496.HKD","LU2417539215.USD","LU0471298777.SGD","IE00B19Z3581.USD","LU0985481810.HKD","LU0949170772.SGD","LU1228905540.USD","LLII","LU2487616109.SGD","SGXZ81514606.USD","LU2471134879.HKD","LU0511384066.AUD","LU1548497426.USD","LU0256863811.USD","BK4588","IE000F7OJYX1.SGD","LU0795875086.SGD","PAWZ","IE00B19Z8W00.USD","BK4592","LU1366192091.USD","IE0002270589.USD","LU0994945656.USD","LU0889565916.HKD","LU0256863902.USD","ELIL","LU2023250330.USD","LU0124676726.USD","LU0070302665.USD","LU0251132253.USD","LU2129689514.USD","LU2237443465.HKD","LU2168564222.USD","LU2756315318.SGD","IE00BKVL7J92.USD","SG9999014906.USD","LU1037948541.HKD","LU2362540622.SGD","BK4532","LU2430703251.USD","LU0058720904.USD","IE000SO60NU8.SGD","LU0306807586.USD","LU0528227936.USD","LU1061106388.HKD","CURE","LU0266013472.USD","LU1720051108.HKD","LU1868837300.USD","SGXZ57979304.SGD","SG9999002232.USD","IE00BZ1G4Q59.USD","LU2125154778.USD","LU1868836591.USD","LU1718418525.SGD","LU1868837136.USD","SG9999003800.SGD","UNHW","SG9999015341.SGD","LU1221951046.USD","SG9999011175.SGD","LU2430703095.HKD","BK4550","LU1035773651.USD","LU2461242641.AUD","LU0203347892.USD","ELIS","LU1814569148.SGD","SG9999015945.SGD","LU0942090050.USD","UNHU","LU0823416689.USD","SG9999001440.SGD","LU0011850046.USD","SG9999015978.USD","LU2129689431.USD","RXL","LU0029864427.USD","LU0354030438.USD","LU1988902786.USD","WDNA","LLYX","LU1674673691.USD","LU0162691827.USD","LU2362541513.USD","IE00B42XCP33.USD","LU1244550221.USD","LU1712237335.SGD","SG9999002224.SGD","IE00B1XK9C88.USD","IE00BJJMRX11.SGD","IE00BDGV0183.EUR","PBE","LU0289739343.SGD","LU1093756325.SGD","LU0130517989.USD","LU2361044865.SGD","LU0545562505.USD","LU1121112475.USD","IE00B2B36J28.USD","LU0477156953.USD","LU2023251221.USD","LU1551013342.USD","LU0820561909.HKD","LU0098860793.USD","LU0471298694.HKD","BBH","LU1674673428.USD","LU1923622614.USD","LU1854103824.USD","LU1699723380.USD","LU2471134523.USD","LU0345769631.USD","LU2347655156.SGD","04332","IE00BVYPNV92.GBP","LU0079474960.USD","IHE","LU0345770308.USD","LU1232071149.USD","PFE","LU1244550494.USD","LU1941712264.USD","LU0316494557.USD","LU2552382058.USD","PPH","IE0005OL40V9.USD","LU2129689605.HKD","IE00BFTCPJ56.SGD","LU0203202063.USD","UNHG","LU0683600562.USD","LU0342679015.USD","LU2028103732.USD","LU0640476718.USD","SG9999015358.SGD","LU2089984988.USD","NVOX","IE00B894F039.SGD","LU1059921491.USD","LU2347655073.USD","LU1267930490.SGD","BK4578","SG9999014898.SGD","IE00B7KXQ091.USD","LLYZ","LU2125154935.USD","LU2242646821.SGD","LU1066051225.USD","LU1057294990.SGD","LU0210536198.USD","IE0000B7K699.USD","LU1430594728.SGD","LU1670627923.USD","LU0496365809.HKD","BK4568","IE000M9KFDE8.USD","LU1116320737.USD","LU1894683264.USD","IE00BVYPNW00.USD","LU2236285917.USD","LU0353189680.USD","SG9999001176.SGD","SG9999018865.SGD","LU1941712348.USD","LU0211331839.USD","LU1127390331.HKD","LU1035775433.USD","FTXH","LU0980610538.SGD","SG9999014567.USD","IE00B19Z8X17.USD","LU0965509101.SGD","OZEM","LU2237443549.SGD","LU0211326839.USD","LU0096364046.USD","IYH","LU2211815571.USD","LU0107464264.USD","LU0786609619.USD","SG9999014914.USD","LU1093756168.USD","IE00BJJMRZ35.SGD","LU1868836914.USD","LU1623119135.USD","LU1496350171.SGD","LU0310800379.SGD","LU2954938101.SGD","BK4566","TBXU","GDOC","LU1791710400.SGD","LU1914381329.SGD","LU0320765059.SGD","LU0106261372.USD","LU1720051017.SGD","LU2462591350.SGD","LU1935042991.SGD","LU0345770993.USD","LU1228905037.USD","TMED","LU0069063385.USD","LU0964807845.USD","LU1934455277.USD","NVOH","LU1043141123.HKD","IE00B3PB1722.GBP","LU1221951129.SGD","LU1267930573.SGD","LU0158827948.USD","IE00B3T34201.USD","IE00BN8TJ469.HKD","LU0077335932.USD","SGXZ99366536.SGD","LU1571399168.USD","LU1670628061.USD","LU0158827781.USD","LU2087621335.USD","SG9999014880.SGD","LU2505996509.AUD","IE00BLSP4452.SGD","LU1868836757.USD","03165","LU0648001328.SGD","LU0170899867.USD","LU2237443382.USD","LU0057025933.USD","IE00B19Z9505.USD","VHT","LU0456855351.SGD","LU0154236417.USD","LU1732800096.USD","LU0868494708.USD","LU2125909247.SGD","LU1066051811.HKD","BK4154","LU2360032135.SGD","JDOC","LLY","IE00BN29S564.USD","LU0354030511.USD","LU0133085943.USD","IE0004445015.USD","LU2491050071.SGD","IE00BBT3K403.USD","THNR","LU1196500208.SGD","LU2756315664.SGD","IE00BK4W5L77.USD","RHHBY","LU2596442595.SGD","LU0174119429.USD","BK4581","IE00B7SZLL34.SGD","SG9999001176.USD","LU0395794307.EUR","LU1496350502.SGD","LU1551013425.SGD","LU0823434740.USD","LU0211326755.USD","LU0225283273.USD","LU2361045086.USD","LU2468319806.SGD","LU0061475181.USD","LU2360106947.USD","LU2125909593.SGD","LU0792757196.USD","XLV","LU0345769128.USD","LU0097036916.USD","SG9999014559.SGD","LU2602419157.SGD","CANC","GB00BDT5M118.USD","LU1261432733.SGD","LU1162221912.USD","LU1989772923.USD","LU0321505439.SGD","IE000MB6IJN5.SGD","IE00BJJMRY28.SGD","SG9999014542.SGD","LU0006306889.USD","LU2271345857.HKD","NVO","MHIP","LU0882574055.USD","IE00BFSS8Q28.SGD","LU1201861249.SGD","LU2433249047.HKD","LU0203345920.USD","LU1116320901.HKD","AGNG","LU0976567544.SGD","LU0310800965.SGD","LU0426417589.USD","BK4534","LU0912757837.SGD","IE000BZT7R73.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU0943347566.SGD","PJP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654407006","title":"Meta和貝萊德將在德克薩斯州EL Paso開發數據中心園區 由後者持股80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654407006","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654407006?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 17:42","pubTimestamp":1785231720,"startTime":"0","endTime":"0","summary":"根据声明，Meta和贝莱德成立了一家合资企业，将在德克萨斯州El Paso开发和持有数据中心园区。\n　　贝莱德的基金将持有80%的权益；Meta持有剩余的20%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：江学思","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-28/doc-inikizzz2507496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["IDGT","LU0130102774.USD","LU1280957306.USD","LU2404859667.USD","LU0731783394.SGD","TSLA","WDAI","GOOG","EL","BK4567","AAPL","META","AIO","WISE","BK4533","YMAG","GLAM","HPEL","IE00BGHQF631.EUR","LU2592432038.USD","IE00BGHQF748.EUR","PBOT","BLK","BK4183","LU0320765489.SGD","LU2552382215.SGD","CLDL","BULZ","AIFD","SOCL","FMET","IE00B64PRP62.GBP","BK4535","FCLD","LU2430703251.USD","MAGY","SKYY","AIBU","NVDA","IE00BDGV0183.EUR","IE00BVYPNV92.GBP","BLOK","DTCR","CLOU","LU2505996681.GBP","WPAI","MSFT","FDFF","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654482830","title":"Sarepta任命前艾伯維高管塞韋裏諾為首席執行官後股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2654482830","media":"路透中文","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654482830?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 21:05","pubTimestamp":1785157512,"startTime":"0","endTime":"0","summary":"BUZZ-Sarepta任命前艾伯维高管塞韦里诺为首席执行官后股价上涨7月27日-** 基因治疗公司Sarepta Therapeutics的股价在盘前交易中上涨7.1%，至16.8美元** 该公司任命  的迈克尔·塞韦里诺为首席执行官，自7月28日起生效** 塞韦里诺将接替道格·英格拉姆的职位，后者即将退休，并将担任顾问职务至年底，以确保平稳过渡**在加入该公司之前，塞韦里诺曾担任Tessera Therapeutics的首席执行官，此前还曾在艾伯维担任副董事长兼总裁ABBV.O** 截至上一交易日收盘，该股今年以来累计下跌27.1%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL4T43T11Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739343.SGD","RXL","AGNG","LU2237443978.SGD","LU1670627923.USD","IE00B2B36J28.USD","IYH","LU0689472784.USD","LU1732799900.SGD","IXJ","SG9999015986.USD","LU0689626769.HKD","LU0553294199.USD","LU0949170772.SGD","IE00BVYPNV92.GBP","LU0965509010.AUD","PPH","LU2433249047.HKD","LU1037948897.HKD","LU0170899867.USD","IE000BZT7R73.USD","PJP","LU1244550221.USD","SRPU","LU1934455277.USD","FTXH","BK4550","IE00B4R5TH58.HKD","VHT","LU0203345920.USD","LU0234572021.USD","BK4559","BK4533","JDOC","GLAM","ABBV","LU0820561909.HKD","SRPT","TRUH","MEDX","SG9999001440.SGD","FHLC","LU0310799852.SGD","LU0868494617.USD","LU0965508806.USD","IE000F7OJYX1.SGD","XLV","BK4534","IE0009355771.USD","LU1989772840.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106583056","title":"Kenvue 宣佈：FDA 授予泰諾新非處方配方三年市場獨佔權","url":"https://stock-news.laohu8.com/highlight/detail?id=1106583056","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106583056?lang=zh_tw&edition=fundamental","pubTime":"2026-07-25 02:17","pubTimestamp":1784917050,"startTime":"0","endTime":"0","summary":"7月24日——Kenvue 公司披露，美国食品药品监督管理局已正式批准泰诺与萘普生的复方制剂。这是市面上首款，也是唯一一款含有对乙酰氨基酚和萘普生钠的非处方固定剂量组合产品。不仅如此，FDA还授予了该新配方长达三年的市场独占权。这一举措，无疑为Kenvue在非处方止痛药领域的布局提供了坚实的护城河。据Kenvue方面透露，这款名为“泰诺与萘普生”的新品很快将在美国各大主要零售商上架销售。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930813.SGD","IE00B3T34201.USD","BK4183","BK4585","KVUE","LU0792757196.USD","IE00BFXG1179.USD","LU0128525929.USD","LU0310800379.SGD","GLAM","LU0708994859.HKD","LU1267930573.SGD","LU0029864427.USD","LU0889566641.SGD","RSPS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128949873","title":"FDA批准泰諾®與萘普生複方製劑：首款非處方對乙酰氨基酚（650毫克）與萘普生鈉（220毫克）固定劑量組合","url":"https://stock-news.laohu8.com/highlight/detail?id=1128949873","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128949873?lang=zh_tw&edition=fundamental","pubTime":"2026-07-25 02:01","pubTimestamp":1784916077,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式批准泰诺®与萘普生复方制剂上市。这款产品是首款且唯一一款非处方固定剂量组合药物，其成分为对乙酰氨基酚（650毫克）与萘普生钠（220毫克）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","LU1267930573.SGD","LU0708994859.HKD","GLAM","LU0029864427.USD","LU1267930813.SGD","BK4585","KVUE","LU0792757196.USD","RSPS","LU0128525929.USD","IE00B3T34201.USD","BK4588","LU0310800379.SGD","BK4183","LU0889566641.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653035035","title":"美國FDA批准非處方泰諾複方止痛片","url":"https://stock-news.laohu8.com/highlight/detail?id=2653035035","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653035035?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 23:56","pubTimestamp":1784908596,"startTime":"0","endTime":"0","summary":"美国FDA批准非处方泰诺复方止痛片路透7月24日-美国食品和药物管理局周五批准了一种非处方固定剂量片剂，该药将Kenvue公司的KVUE.N泰诺与非甾体抗炎药萘普生结合，可提供长达12小时的止痛效果。FDA表示，此次批准符合特朗普的“伟大医疗计划”，该联邦计划旨在让更多经过验证的安全药品可供非处方购买。此前，美国卫生官员对孕期服用泰诺与自闭症之间据称存在的关联表示担忧，泰诺因此受到密切关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nL4S43Q1CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","LU0310800379.SGD","IE00B3T34201.USD","LU1585245621.USD","KVUE","LU1571399168.USD","BK4183","LU0792757196.USD","IE00BFXG1179.USD","LU0889566641.SGD","BK4588","LU0128525929.USD","BK4504","LU0029864427.USD","LU0708994859.HKD","LU2463526074.USD","BK4585","GLAM","SG9999001440.SGD","BK4018","BK4567","LU1267930813.SGD","RSPS","LU1267930573.SGD","KMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164500582","title":"美國FDA批准首款對乙酰氨基酚/萘普生非處方組合產品——泰諾聯用萘普生，提供12小時鎮痛效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1164500582","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164500582?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 22:48","pubTimestamp":1784904499,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）近日正式批准了泰诺（Tylenol）与萘普生（Naproxen）的联合用药方案。这是首款非处方（OTC）复方制剂，将对乙酰氨基酚（Acetaminophen）与萘普生（Naproxen）合二为一，专为缓解疼痛而设计，其药效可长达12小时。这一创新组合，有望为饱受疼痛困扰的患者提供更持久、更便捷的镇痛选择，无需频繁服药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0708994859.HKD","KVUE","LU0029864427.USD","RSPS","IE00BFXG1179.USD","LU1267930573.SGD","GLAM","BK4588","LU0792757196.USD","LU0889566641.SGD","IE00B3T34201.USD","LU1267930813.SGD","LU0128525929.USD","BK4585","LU0310800379.SGD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108936974","title":"艾利科技推出全新創新成果，藉助整合型Align™數字平台提升Invisalign®治療方案規劃與患者參與度","url":"https://stock-news.laohu8.com/highlight/detail?id=1108936974","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108936974?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 04:43","pubTimestamp":1784839410,"startTime":"0","endTime":"0","summary":"艾利科技（Align Technology）近日宣布一系列全新创新举措。这些成果旨在进一步推动Invisalign®治疗方案规划的进步。同时，通过其整合型Align™数字平台，患者参与度也将得到显著增强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4534","LU2106854487.HKD","LU1974910355.USD","LU1917777945.USD","BK4198","BK4588","LU2023250504.SGD","LU2023250843.SGD","ALGN","GLAM","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135293473","title":"Genmab與艾伯維就Epcoritamab（Duobody®-CD3xCD20）治療復發/難治性瀰漫大B細胞淋巴瘤的3期EPCORE® DLBCL-1試驗作出澄清","url":"https://stock-news.laohu8.com/highlight/detail?id=1135293473","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135293473?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 04:01","pubTimestamp":1784836901,"startTime":"0","endTime":"0","summary":"Genmab与艾伯维公司（AbbVie）日前就备受关注的3期EPCORE® DLBCL-1临床试验发布了最新澄清说明。该试验旨在全面评估Epcoritamab（Duobody®-CD3xCD20）这一创新疗法在复发或难治性弥漫大B细胞淋巴瘤（DLBCL）患者中的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000SO60NU8.SGD","LU1551013425.SGD","LU0029864427.USD","BK4559","LU0256863902.USD","LU1093756168.USD","LU0868494617.USD","LU1718418525.SGD","LU2125909247.SGD","IE00BJT1NW94.SGD","IE000F7OJYX1.SGD","LU0417517546.SGD","LU0122379950.USD","LU0820561818.USD","LU1989771016.USD","IE00BVYPNV92.GBP","IE00BSNM7G36.USD","LU0965509283.SGD","LU2023251221.USD","LU1057294990.SGD","LU1037948897.HKD","MEDX","LU2089283258.USD","LU1093756325.SGD","LU2237443382.USD","LU1585245621.USD","LU1839511570.USD","LU1244550221.USD","LU0289739343.SGD","LU0965508806.USD","BK4139","IE000MB6IJN5.SGD","XLV","IE00BLSP4239.USD","LU2347655156.SGD","LU0069063385.USD","LU0058720904.USD","SG9999011175.SGD","LU0661504455.SGD","LU0124676726.USD","IE00B19Z3581.USD","LU0882574055.USD","IE00B42XCP33.USD","IE00BBT3K403.USD","BK4588","LU0511384066.AUD","LU0942090050.USD","LU1267930490.SGD","LU2237443622.USD","LU0795875086.SGD","LU2129689431.USD","LU0320765646.SGD","RXL","LU2357627491.SGD","LU0820561909.HKD","GLAM","LU0868494708.USD","IE0002141913.USD","IE00BLSP4452.SGD","LU0738911758.USD","SG9999001440.SGD","LU0795875169.SGD","BK4585","SG9999015978.USD","LU1732800096.USD","LU0823416689.USD","IE0009355771.USD","LU0545039389.USD","LU1023059063.AUD","LU1670628061.USD","BK4581","SG9999015986.USD","LU0912757837.SGD","LU1989772923.USD","LU1267930573.SGD","LU0158827948.USD","FTXH","LU1934455277.USD","LU1732799900.SGD","LU1003077747.HKD","FHLC","LU0289739699.SGD","LU0861579265.USD","LU2468319806.SGD","LU0689626769.HKD","LU0170899867.USD","LU0203347892.USD","SG9999015952.SGD","SG9999015945.SGD","LU0211328371.USD","LU0098860793.USD","LU0128525929.USD","IE00B4R5TH58.HKD","LU1934455863.HKD","LU0234570918.USD","LU1244550577.SGD","IE0000B7K699.USD","LU0689472784.USD","LU1061106388.HKD","LU0432979614.USD","LU0553294199.USD","IE00BFTCPJ56.SGD","LU0057025933.USD","BK4533","LU0310799852.SGD","LU1496350502.SGD","IE00BGHQF631.EUR","LU1923622614.USD","IE000WAW04H5.SGD","LU0859254822.USD","ABBV","IE0002270589.USD","IE00B19Z3B42.SGD","LU2089984988.USD","LU0289961442.SGD","BK4534","LU1934455194.USD","IE000BZT7R73.USD","LU1291159041.SGD","BK4550","LU2237443895.HKD","LU0256863811.USD","PJP","IE00B3PB1722.GBP","LU2129689605.HKD","LU2087621335.USD","IE00BDGV0183.EUR","IE00BJJMRZ35.SGD","IE00BVYPNW00.USD","LU0456855351.SGD","LU2112291526.USD","IE0004445239.USD","TRUH","LU0310800379.SGD","LU0203345920.USD","LU1162221912.USD","JDOC","IYH","VHT","SG9999003800.SGD","LU0472753341.HKD","LU1670627923.USD","LU0949170772.SGD","IE00B2B36J28.USD","LU0965509101.SGD","IE00BN8TJ469.HKD","LU2433249047.HKD","LU0708994859.HKD","LU0114720955.EUR","LU0211327993.USD","LU2089284900.SGD","LU0985320562.USD","LU2237443978.SGD","LU0234572021.USD","LU1037948541.HKD","IXJ","LU1929549753.HKD","LU2237443549.SGD","LU1551013342.USD","LU2237443465.HKD","LU1989772840.SGD","AGNG","LU2125909593.SGD","LU2129689514.USD","PPH","LU1983299246.USD","LU1244550494.USD","LU0943347566.SGD","LU1074936037.SGD","BK4566","LU0965509010.AUD","LU1496350171.SGD","LU0198837287.USD","LU2133065610.SGD","LU1430594728.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116716506","title":"Genmab澄清：總生存期（OS）作為美國3期Epcore® DLBCL-1試驗的唯一主要終點，但未能達到","url":"https://stock-news.laohu8.com/highlight/detail?id=1116716506","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116716506?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 04:01","pubTimestamp":1784836871,"startTime":"0","endTime":"0","summary":"Genmab公司近日发布声明，对关于其3期Epcore® DLBCL-1临床试验的结果进行了进一步澄清。该公司明确指出，总生存期（OS）是此项试验在美国设定的唯一主要终点。然而，令人遗憾的是，这一关键终点最终并未能成功达到。\n此声明旨在厘清外界对试验数据的理解，避免不必要的误读。总生存期作为衡量患者从治疗开始到死亡时间的最直接指标，其未达到预期结果，对Genmab而言无疑是一个重大挫折。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739343.SGD","LU0882574055.USD","LU0198837287.USD","LU1267930490.SGD","LU1003077747.HKD","IE0000B7K699.USD","LU0158827948.USD","LU2237443895.HKD","LU0310799852.SGD","LU1023059063.AUD","IE000MB6IJN5.SGD","LU0912757837.SGD","LU1585245621.USD","LU1989772840.SGD","LU2237443622.USD","LU1670627923.USD","IE000WAW04H5.SGD","LU0820561818.USD","LU0472753341.HKD","LU2125909593.SGD","IE00B19Z3B42.SGD","LU0456855351.SGD","LU1934455277.USD","LU2089283258.USD","FTXH","LU0689472784.USD","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","LU0211328371.USD","LU2237443549.SGD","LU0203345920.USD","JDOC","LU0965509010.AUD","LU1057294990.SGD","IE00B3PB1722.GBP","SG9999003800.SGD","LU1929549753.HKD","SG9999015945.SGD","LU0069063385.USD","BK4559","IE00B19Z3581.USD","LU2112291526.USD","LU1267930573.SGD","LU0122379950.USD","LU0689626769.HKD","LU1839511570.USD","LU1162221912.USD","LU0114720955.EUR","LU0553294199.USD","LU0868494617.USD","LU1923622614.USD","LU1061106388.HKD","LU1496350502.SGD","LU0256863902.USD","LU1430594728.SGD","LU1983299246.USD","BK4550","AGNG","LU0738911758.USD","IE00BBT3K403.USD","LU0820561909.HKD","RXL","LU0708994859.HKD","LU0320765646.SGD","LU0124676726.USD","LU1732799900.SGD","XLV","IE0004445239.USD","IE0009355771.USD","LU2237443382.USD","LU1291159041.SGD","LU2347655156.SGD","LU2468319806.SGD","ABBV","IE00B4R5TH58.HKD","LU1093756168.USD","LU0861579265.USD","LU2125909247.SGD","LU2129689605.HKD","LU0868494708.USD","LU0661504455.SGD","LU1244550221.USD","LU1551013425.SGD","LU1037948897.HKD","LU0949170772.SGD","LU1989771016.USD","LU2023251221.USD","BK4588","MEDX","LU1934455863.HKD","LU1670628061.USD","LU0203347892.USD","LU0289739699.SGD","LU1244550577.SGD","LU0823416689.USD","IE00BVYPNW00.USD","LU1037948541.HKD","SG9999015986.USD","IE00B2B36J28.USD","LU0942090050.USD","LU2087621335.USD","TRUH","LU2433249047.HKD","BK4534","LU0859254822.USD","BK4585","LU2237443465.HKD","LU1074936037.SGD","IE00BN8TJ469.HKD","LU0128525929.USD","PJP","SG9999011175.SGD","IE00BJT1NW94.SGD","LU2357627491.SGD","LU0943347566.SGD","LU0545039389.USD","PPH","SG9999015952.SGD","LU0965508806.USD","IYH","GLAM","IE00BFTCPJ56.SGD","IE00BGHQF631.EUR","LU1989772923.USD","LU2089284900.SGD","IE000BZT7R73.USD","LU0029864427.USD","LU0985320562.USD","LU0058720904.USD","LU1551013342.USD","SG9999001440.SGD","LU2129689431.USD","LU1718418525.SGD","LU0211327993.USD","LU0256863811.USD","LU0098860793.USD","LU0289961442.SGD","IXJ","LU2089984988.USD","IE00BDGV0183.EUR","IE00BLSP4452.SGD","BK4139","LU1496350171.SGD","LU0965509101.SGD","LU0795875169.SGD","LU0310800379.SGD","SG9999015978.USD","LU1732800096.USD","BK4533","IE00B42XCP33.USD","IE0002270589.USD","IE000F7OJYX1.SGD","LU0170899867.USD","IE0002141913.USD","LU0965509283.SGD","FHLC","LU0234570918.USD","LU2133065610.SGD","LU0432979614.USD","LU1244550494.USD","IE00BLSP4239.USD","LU0234572021.USD","LU0057025933.USD","LU1934455194.USD","IE00BVYPNV92.GBP","LU0511384066.AUD","BK4566","LU2237443978.SGD","BK4581","VHT","IE000SO60NU8.SGD","LU2129689514.USD","LU1093756325.SGD","LU0417517546.SGD","LU0795875086.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109432677","title":"FDA顧問委員會投票支持將Bpc-157肽納入允許藥房配製清單，Hims & Hers Health股價飆升10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109432677","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109432677?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 00:51","pubTimestamp":1784825499,"startTime":"0","endTime":"0","summary":"Hims & Hers Health Inc.股价上涨10%。这一涨势的催化剂是什么？FDA顾问委员会刚刚投票决定，将Bpc-157肽列入允许药房配制的清单中。该决定一经公布，市场随即作出强烈反应。投资者普遍认为，此举将为相关公司开辟新的业务增长路径。Bpc-157作为一种备受关注的肽类物质，如今获得监管层面的积极信号，无疑让市场情绪瞬间高涨。从消息公布到股价反应，整个过程可谓迅速而剧烈，显示出投资者对该领域前景的高度期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMY","HIMS","BK4196","GLAM","THNR","HMYY","HIMZ","HEAL","HIYY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653837722","title":"FDA顧問小組投票決定將廣受歡迎的肽BPC-157列入複方製劑清單","url":"https://stock-news.laohu8.com/highlight/detail?id=2653837722","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653837722?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 00:43","pubTimestamp":1784824996,"startTime":"0","endTime":"0","summary":"FDA顾问小组投票决定将广受欢迎的肽BPC-157列入复方制剂清单路透7月23日-美国食品和药物管理局（FDA）的一个顾问小组周四投票决定，将一种名为BPC-157的广泛使用的肽列入允许药房进行更广泛配制的清单。八名委员会成员投了赞成票，六名成员投了反对票，一名成员弃权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nL4T43P263:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMS","HIMY","HEAL","HMYY","HIMZ","BK4196","HIYY","THNR","GLAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653724664","title":"美國FDA顧問小組評估肽類限制，業界促放寬","url":"https://stock-news.laohu8.com/highlight/detail?id=2653724664","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653724664?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 00:09","pubTimestamp":1784822960,"startTime":"0","endTime":"0","summary":"拜登政府于2023年发现近20种肽类药物存在安全隐患，并禁止其合法配制。FDA 敦促开展临床试验目前已有许多肽类药物获得了卫生监管机构的批准。而此次会议中正在评估的药物尚未经过此类临床试验，且可在网上轻易购买，无需任何医生监督。FDA的评审人员上个月在文件中曾向专家小组建议，该机构不应支持允许持有州执照的配制药房进行此类操作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nL4S43P23A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMS","HMYY","GLAM","HIMZ","BK4196","HEAL","HIYY","THNR","HIMY"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":7,"totalSize":146,"code":"91000000","status":"200"}]}}